Late second dose or booster of AstraZeneca, baricitinib treatment, trends in emergency admissions for diabetic ketoacidosis

Peer reviewed journals featured:

- A sub-study of two randomised controlled trials on reactogenicity and immunogenicity after a late second or third dose of AstraZeneca [here](#) and associated commentary [here](#)
- A randomised controlled trial of baricitinib for the treatment of hospitalised COVID-19 adults [here](#) and associated commentary [here](#)
- Observational studies on:
  - Outcomes for COVID-19 patients intubated after failure of non-invasive ventilation [here](#)
  - Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes during COVID-19 in England [here](#) and associated commentary [here](#)
- Commentary on COVID-19 cases in Malaysia despite prolonged lockdown [here](#)

Letters and correspondence discussed:

- The incidence of cardiac complications in hospitalised COVID-19 patients in Australia [here](#)
- Telehealth sexual and reproductive healthcare during COVID-19 in NSW [here](#)
- Challenges in delivering telemedicine to vulnerable populations during COVID-19 in Melbourne [here](#)
- The effect of COVID-19 on body weight in people at high risk of type 2 diabetes in England [here](#)

Guidance and reports

- The World Health Organization published an update on COVID-19 vaccine booster doses [here](#)
- The UK National Institute for Health and Care Excellence published a rapid guideline on managing COVID-19 [here](#)

News and blogs

- COVID-19 infection increases the risk of kidney disease even in mild cases [here](#)
- The People’s COVID-19 inquiry on the pandemic’s impact on UK’s population [here](#) and profiteering from the people’s health [here](#)

Click [here](#) to subscribe to the daily evidence digest.